Cytek Biosciences
CTKB
5.43
+0.07
+1.31%
Cytek Biosciences
US · CTKB
#3522 by market cap
Listed 2021
5.43
+0.07
+1.31%
Live - 5344 symbols - heartbeat 138s ago
· 2026-10-09 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 63.43% -0.34pp
- Institutions
- 184 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund37.80%
Hedge Fund16.76%
Individual/Insider8.48%
VC/PE Fund5.12%
Private Company2.31%
Public Company1.06%
Insurance Company0.20%
Government Pension Fund0.15%
Other28.10%
Top holders as of 2026-06-30
BlackRock
7.37% · 9.58M sh
Millennium Management LLC
7.18% · 9.34M sh
Boston Partners Global Investors, Inc.
5.87% · 7.64M sh
Hillhouse Capital Management, Ltd.
5.12% · 6.66M sh
Topline Capital Management, LLC
4.83% · 6.28M sh
Vanguard Capital Management, LLC
4.37% · 5.68M sh
Wenbin Jiang
4.28% · 5.56M sh
Ming Yan
3.71% · 4.82M sh
Geode Capital Management, LLC
2.35% · 3.06M sh
Dimensional Fund Advisors
2.01% · 2.62M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| Wenbin Jiang | Chairperson & CEO | 4.28% |
| Ming Yan | CTO & Director | 3.71% |
| Valerie Barnett | General Counsel | 0.12% |
| William McCombe | Chief Financial Officer | 0.10% |
| Jack Ball | Lead Independent Director | 0.07% |
| Michael Holder | Independent Director | 0.05% |
| Vera Imper | Independent Director | 0.05% |
| Deborah Neff | Independent Director | 0.05% |
| Philippe Busque | Senior Vice President of Global Sales & Services | 0.03% |
| Richard Chin | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Philippe Busque | Senior Vice President of Global Sales & Services | Intent to Sell (Form 144) | -31,666 | $4.63 |
| 2026-08-17 | Glenn Muir | Independent Director | Derivative Exercise and Retained | +3,086 | -- |
| 2026-08-17 | Richard Chin | Independent Director | Derivative Exercise and Retained | +6,107 | -- |
| 2026-08-17 | Michael Holder | Independent Director | Derivative Exercise and Retained | +2,181 | -- |
| 2026-08-17 | William McCombe | Chief Financial Officer | Derivative Exercise and Sale | -11,904 | $4.67 |
| 2026-08-17 | William McCombe | Chief Financial Officer | Derivative Exercise and Retained | +23,516 | -- |
| 2026-08-17 | Wenbin Jiang | Chairperson & CEO | Derivative Exercise and Sale | -36,269 | $4.67 |
| 2026-08-17 | Wenbin Jiang | Chairperson & CEO | Derivative Exercise and Retained | +83,826 | -- |
| 2026-08-17 | Ming Yan | CTO & Director | Derivative Exercise and Sale | -8,088 | $4.67 |
| 2026-08-17 | Ming Yan | CTO & Director | Derivative Exercise and Retained | +25,182 | -- |
| 2026-08-09 | Ilan Feuchtwang | -- | Other Derivative Acquisition | +127,118 | $4.66 |
| 2026-08-09 | Ilan Feuchtwang | -- | Other Derivative Acquisition | +241,416 | -- |
| 2026-06-11 | Ming Yan | CTO & Director | Other Disposition | -135,892 | -- |
| 2026-06-09 | Deborah Neff | Independent Director | Other Derivative Acquisition | +18,261 | $4.05 |
| 2026-06-09 | Deborah Neff | Independent Director | Other Derivative Acquisition | +33,333 | -- |
| 2026-06-09 | Deborah Neff | Independent Director | Derivative Exercise and Retained | +43,973 | -- |
| 2026-06-09 | Glenn Muir | Independent Director | Other Derivative Acquisition | +29,835 | $4.05 |
| 2026-06-09 | Glenn Muir | Independent Director | Other Derivative Acquisition | +55,555 | -- |
| 2026-06-09 | Jack Ball | Lead Independent Director | Derivative Exercise and Retained | +43,973 | -- |
| 2026-06-09 | Richard Chin | Independent Director | Other Derivative Acquisition | +18,261 | $4.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Cytek Biosciences discussion 0 comments